Free Trial
Notice: Trading of Cassava Sciences halted at 08:00 AM EST due to "News pending".
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Price, News & Analysis

Cassava Sciences logo
$1.90 -0.90 (-32.14%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 0.00 (-0.26%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cassava Sciences Stock (NASDAQ:SAVA)

Key Stats

Today's Range
$1.80
$2.33
50-Day Range
$1.90
$2.84
52-Week Range
$1.80
$42.20
Volume
16.20 million shs
Average Volume
2.93 million shs
Market Capitalization
$91.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.50
Consensus Rating
Moderate Buy

Company Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Remove Ads

Cassava Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

SAVA MarketRank™: 

Cassava Sciences scored higher than 78% of companies evaluated by MarketBeat, and ranked 211th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cassava Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cassava Sciences are expected to grow in the coming year, from ($3.97) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cassava Sciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cassava Sciences is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cassava Sciences has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cassava Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    33.01% of the float of Cassava Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cassava Sciences has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Cassava Sciences has recently decreased by 9.35%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cassava Sciences does not currently pay a dividend.

  • Dividend Growth

    Cassava Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    33.01% of the float of Cassava Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cassava Sciences has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Cassava Sciences has recently decreased by 9.35%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cassava Sciences has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Cassava Sciences this week, compared to 8 articles on an average week.
  • Search Interest

    Only 27 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cassava Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.00% of the stock of Cassava Sciences is held by insiders.

  • Percentage Held by Institutions

    Only 38.05% of the stock of Cassava Sciences is held by institutions.

  • Read more about Cassava Sciences' insider trading history.
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

Cassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpoint
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
See More Headlines

SAVA Stock Analysis - Frequently Asked Questions

Cassava Sciences' stock was trading at $2.36 at the start of the year. Since then, SAVA shares have decreased by 19.5% and is now trading at $1.90.
View the best growth stocks for 2025 here
.

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its earnings results on Monday, March, 3rd. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.11.

Shares of Cassava Sciences split before market open on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

Cassava Sciences' top institutional shareholders include Affinity Asset Advisors LLC, Group One Trading LLC, Bank of America Corp DE and Two Sigma Advisers LP (1.26%). Insiders that own company stock include Eric Schoen and James William Kupiec.
View institutional ownership trends
.

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
3/03/2025
Today
3/25/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SAVA
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.50
High Stock Price Target
$107.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+2,768.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-97,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.26 per share
Price / Book
0.58

Miscellaneous

Free Float
43,780,000
Market Cap
$91.79 million
Optionable
Optionable
Beta
-1.24
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SAVA) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners